There were no significant differences in all the B cells immune profiles in ET patients with or without hydroxyurea treatment, except lower IL-1β expression level in B cells (median 6.9% vs 16.4%, p = 0.014) was found in ET patients being treated with hydroxyurea (Table 1 and Supplementary Table S1). Here, IL1B is linked to essential thrombocythemia.